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Objectives: To review the pathophysiology, co-morbidities, and therapeutic options for psoriasis,
psoriatic arthritis and rheumatoid arthritis in order to further understand the similarities and differences
in treatment paradigms in the management of each disease. New targets for individualized therapeutic
decisions are also identiﬁed with the aim of improving therapeutic outcome and reducing toxicity.
Search strategy: Using the PubMed database, we searched literature published from 2000 to 2015 using
combinations of the key words “psoriasis,” “psoriatic arthritis,” “rheumatoid arthritis,” “pathogenesis,”
“immunomodulation,” and “treatment.”
Inclusion and exclusion criteria: This was a non-systematic review and there were no formal inclusion
and exclusion criteria.
Data extraction: Abstracts identiﬁed in the search were screened for relevance and articles considered
appropriate evaluated further. References within these selected articles were also screened. Information
was extracted from 198 articles for inclusion in this report.
Data synthesis: There was no formal data synthesis. Articles were reviewed and summarized according
to disease area (psoriasis, psoriatic arthritis, and rheumatoid arthritis).
Headline results: The pathophysiology of psoriasis, psoriatic arthritis, and rheumatoid arthritis involves
chronic inﬂammation mediated by pro-inﬂammatory cytokines. Dysfunction in integrated signaling
pathways affecting different constituents of the immune system result in varying clinical features in the
three diseases. Co-morbidities, including cardiovascular disease, malignancies, and non-alcoholic fatty
liver disease are increased. Increased understanding of the immunopathogenesis allowed development
of targeted treatments; however, despite a variety of potentially predictive genetic, protein and cellular
biomarkers, there is still signiﬁcant unmet need in these three inﬂammatory disorders.
& 2016 The Authors. Published by Elsevier HS Journals, Inc. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Psoriasis is a chronic, immune-mediated, systemic disorder
with a worldwide prevalence of 0.9–8.5% [1,2]. Psoriasis leads to
sustained inﬂammation and epidermal hyperplasia, ultimately
resulting in the formation and persistence of lesions, which are
commonly located on the scalp, elbows, knees, umbilicus, and
lumbar area [3–5]. Psoriasis impacts patients both physically andr HS Journals, Inc. This is an open
Communications, provided
, Pﬁzer Inc. provided ﬁnancial
full responsibility for article
e article.
ll@hotmail.compsychologically, with patients reporting reduction in physical and
mental function comparable to that seen in diseases such as
cancer, arthritis, heart disease, and depression [6,7], leading to
marked quality of life impairment [8].
Psoriatic arthritis is a seronegative, chronic, inﬂammatory
arthropathy often associated with psoriasis [9–11]. Prevalence
estimates in the general population show marked variability,
possibly due to variations in epidemiological study methodology
[12]. However, using newer classiﬁcation criteria, the estimated
prevalence ranges from 0.16% to 0.25% [13–16]. Psoriatic arthritis
may affect between 20% and 30% of patients with psoriasis [17]
and is characterized by synovial hyperplasia and immune
cell inﬁltration and expansion in both skin and synovium [9].
Patients experience pain, swelling, and joint tenderness, which
produce reduced functioning in daily activities and impaired
quality of life [18].access article under the CC BY-NC-ND license
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disease characterized by synovial inﬂammation and destruction
of joints. Rheumatoid arthritis affects about 0.5–1.0% of adults in
developed countries [19], but 0.4% in South East Asia, and 0.37% in
the Eastern Mediterranean region [20]. Prevalence rises with age
and is higher in women than men [20,21]. Persistent joint
inﬂammation and progressive joint damage eventually result in
disability and decreased quality of life [18,22]; many patients have
to cope with pain, depression, and fatigue [23,24].
Here we review the pathophysiology, co-morbidities, and
therapeutic options for each disease in an attempt to better
understand the similarities and differences in treatment para-
digms in the management of each disease.Literature search
Using the PubMed database, we reviewed literature pertaining
to the role of inﬂammation in the pathogenesis of psoriasis,
psoriatic arthritis, and rheumatoid arthritis. We used different
combinations of the key words “psoriasis,” “psoriatic arthritis,”
“rheumatoid arthritis,” together with “pathogenesis” or “immuno-
modulation,” and with or without the key word “treatment.” An
example of one such combination was (psoriasis OR psoriatic
arthritis OR rheumatoid arthritis) AND (pathogenesis OR immu-
nomodulation) together with either (…OR treatment) or (…AND
treatment) according to response. Our search covered the period
from 2000 to 2015, but the majority of the short-listed articles
were published between 2005 and 2014. Abstracts were screened
for relevance; as this was not a systematic review, no formal
inclusion and exclusion criteria were applied—abstracts were
short-listed for full review if the studies were considered well
designed and the ﬁndings relevant. Articles deemed appropriate
were evaluated further and references within these selected
articles were also reviewed. All types of articles, including reports
of clinical trials, observational studies, literature reviews, and
meta-analyses, were included if considered suitable.Immunopathogenesis
Psoriasis, psoriatic arthritis, and rheumatoid arthritis have both
similar and different clinical features. This likely reﬂects under-
lying genetic heterogeneity, with some genes implicated in patho-
genesis common between the diseases, and other genes
contributing to the distinct pathogenesis of each disease [25–27].
Studies suggest that each disease arises through integrated and
complex signaling pathways which affect different constituents of
the immune system [27–29], and have distinct roles in the patho-
genesis of each disease [4,9,30,31]. It is clear that for all three
diseases, both innate as well as adaptive immune responses are
involved (Fig. 1A) [32–39]. Broadly, chronic inﬂammation medi-
ated by T helper (Th)17 and Th1 cells is key in psoriasis [40,41],
while activated T cells and macrophages are important in psoriatic
arthritis [42]. In rheumatoid arthritis, T cells, B cells, and the
concerted interaction of pro-inﬂammatory cytokines play key roles
in disease pathophysiology [43].
Psoriasis
A total of 36 genes are thought to account for 22% of psoriasis
heritability [44], and more than 16 genetic loci have conﬁrmed
association with psoriasis susceptibility [45]. HLA-Cw6 on chro-
mosome 6 is considered to be the risk variant in the PSOR1 (MIM
177900) susceptibility locus that confers the greatest risk of early
onset psoriasis [46]. The identiﬁed susceptibility genes are involvedin the interleukin (IL)-23/Th17 axis of psoriasis immunopatho-
genesis [47].
Abundant expression of chemerin in psoriatic skin induces the
inﬁltration of plasmacytoid dendritic cells to the dermis and
epidermis; these release interferon-alpha (IFN-α), leading to the
activation and maturation of myeloid dendritic cells. These cells
locate to lymph nodes where they present antigens and release co-
stimulatory signals and cytokines [IL-6, IL-12, IL-23, and interferon
(IFN)-γ], thus inducing differentiation of naïve T cells into effector
subsets and clonal expansion (Fig. 1A). T helper cells circulate back
to the epidermal and dermal tissues, where a complex interaction
between various cells and cytokines causes continued proliferation
of keratinocytes and ongoing recruitment of T cells [38]. Cytokines
implicated in the pathogenesis of psoriasis include Th1-associated
[tumor necrosis factor (TNF)-α, IFN-γ and IL-2] and Th17-
associated (IL-17A, IL-17F, IL-22, IL-26, and TNF-α) proteins, which
are increased in serum and lesional skin [36], together with IL-23,
IL-20, and IL-15 [36,48].Psoriatic arthritis
Family studies suggest a large genetic contribution to psoriatic
arthritis, particularly HLA-Cw*0602, IL-23R, and IL-12B [49], and
the identiﬁed genes overlap with those of psoriasis. The lack of
identiﬁed genetic susceptibility loci has been attributed to the
lower prevalence and greater heterogeneity of psoriatic arthritis
[44]. Psoriatic arthritis is thought to occur in genetically primed
individuals, in which the immune response is disrupted, giving rise
to immune cell inﬁltration as well as cytokine release [42].
Inﬁltrating cells, such as activated T cells and macrophages, are
thought to play important roles in the induction of inﬂammatory
and destructive processes in joint tissues, as well as inducing
psoriasis in the skin [42,50].
T-cell-derived inﬂammatory cytokines such as IL-1β, IL-2, IL-10,
IFN-γ, and TNF-α are also dominant in the synovium [42,51].
Involvement of the IL-22 and IL-23/Th17 axis has also been
implicated in psoriatic arthritis [52,53]. IL-17 genes were upregu-
lated more in skin than in synovium from paired psoriatic arthritis
synovial tissue and skin samples, whereas TNF pathway upregu-
lation was similar at both sites. Angiogenesis-related genes and IL-
6 expression were upregulated in synovium but not in skin [54]. A
recent review of psoriatic arthritis pathogenesis indicated that
there may be four clinical phenotypes, synovial predominant,
entheseal predominant, axial predominant, and mutilans, deter-
mined by genotype [55].Rheumatoid arthritis
Genetic factors play a vital role in susceptibility to rheumatoid
arthritis, with heritability between 50% and 60%. The human
leukocyte antigen (HLA) locus accounts for over 30% of the overall
genetic risk; non-HLA genes such as TNF-α have also been
identiﬁed [56].
The pathogenesis of rheumatoid arthritis is characterized by
inﬂammatory inﬁltrates in the synovium and synovial ﬂuid, with a
complex interplay between the adaptive and innate immune
systems. Dendritic cells, mast cells, macrophages, and neutrophils
have important roles in the different aspects of the disease [57].
T and B cells produce auto-antibodies and immune complexes, and
secrete cytokines. In particular, T- and B-cell-associated phosphoi-
nositide-3-kinases delta and gamma (PI3Kδ and γ), signaling
molecules involved in the function of neutrophils and mast cells,
have been implicated in the pathogenesis of rheumatoid arthritis.
Fig. 1. (A) The cells and cytokines involved in the pathogenesis of psoriasis, psoriatic arthritis, and rheumatoid arthritis and (B) the intracellular signaling pathways involved
in the pathogenesis of psoriasis, psoriatic arthritis, and rheumatoid arthritis and the targets for therapies (Reproduced of Annual Review of Pathology. 7, by Annual Reviews,
http://www.annualreviews.org.). Ada, adalimumab; Ana, anakinra; Apr, apremilast; Cert, certolizumab; Etan, etanercept; Gol, golimumab; IFN, interferon; IL, interleukin; Inf,
inﬂiximab; MHC, major histocompatibility complex; PsA, psoriatic arthritis; Pso, psoriasis; RA, rheumatoid arthritis; Rit, rituximab; TCR, T-cell receptor; TGF, tumor growth
factor; Th, T helper cells; TNF, tumor necrosis factor; Toc, tocilizumab; Tofa, tofacitinib; Ust, ustekinumab.
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Immune-mediated inﬂammatory diseases can be associated
with a variety of co-morbidities, including infections [58], malig-
nancies [58–61], depression and anxiety [62], cardiovascular
complications [63–68], non-alcoholic fatty liver disease (NAFLD)
[69], and obesity [70]. Three of the most common and clinically
signiﬁcant co-morbidities are described below.Cardiovascular co-morbidities
In a recent population-based cohort study, after adjustment for
traditional risk factors, the risk of major adverse cardiovascular
events was higher in patients with psoriasis [hazard ratio (HR) ¼
1.08], psoriatic arthritis (HR ¼ 1.24), and rheumatoid arthritis
(HR ¼ 1.39) not prescribed a disease-modifying anti-rheumatic
drug (DMARD), than unexposed controls [71].Psoriasis
Psoriasis has been linked to an increased risk of adverse
cardiovascular events and all-cause mortality [72]. Studies have
conﬁrmed an increased risk of myocardial infarction [73] and
stroke [74]; the relative risk increased with young age and disease
severity. In another study, severe psoriasis conferred an excess
6.2% absolute risk in the 10-year rate of adverse cardiac events vs.
the normal population, even after adjusting for traditional cardi-
ovascular risk factors [66]. Recent systematic reviews have con-
ﬁrmed the increased risk of cardiovascular morbidity in psoriasis
[63,65].
Anti-inﬂammatory medication and TNF-α inhibitor treatment
of patients with psoriasis may lower markers of cardiovascular risk
including C-reactive protein, IL-6, and homocysteine levels [75]. In
a recent systematic review of patients with psoriasis and/or
psoriatic arthritis, the risk of cardiovascular events was signiﬁ-
cantly reduced [relative risk (RR) ¼ 0.75] by systemic treatment
[76]. Other recent reviews show a reduced risk with TNF inhibitors
but not consistently with methotrexate [77,78]. Long-term uste-
kinumab was considered to decrease major adverse cardiovascular
events in patients with psoriasis [78].Psoriatic arthritis
Patients with psoriatic arthritis show an increased risk of
myocardial infarction, angina, and hypertension compared with
the general population [64,65]. As with psoriasis, in addition to the
known risk factors for cardiovascular disease (diabetes and hyper-
lipidemia), disease severity is an important predictor of cardiovas-
cular morbidity in patients with psoriatic arthritis.Rheumatoid arthritis
Rheumatoid arthritis is also a risk factor for cardiovascular
disease, with rates of events being highest in older patients
[68,79,80]. Increased risk of atrial ﬁbrillation, stroke and hyper-
tension have been shown [81,82]. Systemic inﬂammation confers a
signiﬁcant additional risk for cardiovascular death among patients
with rheumatoid arthritis, even after controlling for common
cardiovascular co-morbidities and risk factors [83].
A systematic literature review found a signiﬁcantly reduced risk
of all cardiovascular events in rheumatoid arthritis after treatment
with TNF inhibitors (RR ¼ 0.7) and methotrexate (RR ¼ 0.72) and
an increased risk after corticosteroid (RR ¼ 1.47) and non-steroidal
anti-inﬂammatory treatment (RR ¼ 1.18) [76].Malignancies
Psoriasis
An increased risk of melanoma [84] and non-melanoma skin
cancers (NMSC) [85,86] has been demonstrated in psoriasis
patients. A recent systematic review and meta-analysis showed a
small increased risk of some solid cancers associated with smoking
and alcohol use in patients with psoriasis [61]. In an analysis of US
claims data, patients with psoriasis had higher rates of malignancy
than the general population; there was little difference in malignancy
rates between patients receiving different treatments (non-biologic
systemics, etanercept, other TNF-α inhibitors, and phototherapy),
except for phototherapy [87].Psoriatic arthritis
A cohort analysis of patients with psoriatic arthritis reported
that 10.2% of patients developed cancer; however, this incidence
did not differ from that in the general population [88]. Another
study reported that malignant neoplasms were the third leading
cause of death (17.0%) among patients with psoriatic arthritis after
diseases of the circulatory and respiratory systems [89].Rheumatoid arthritis
A study of cancer incidence between 1977 and 1987 in 20,699
patients with rheumatoid arthritis, reported increases in non-
Hodgkinʼs lymphoma, Hodgkinʼs disease, lung cancer, and non-
melanoma skin cancer, supporting ﬁndings suggesting positive
associations between rheumatoid arthritis and non-Hodgkinʼs
lymphoma, Hodgkinʼs disease, and lung cancer [90]. Another
population-based study reported 20–50% increased risks for
smoking-related cancers and a 470% increased risk for non-
melanoma skin cancer [59].
Many of the malignancies are associated with psoriasis and
rheumatoid arthritis rather than psoriatic arthritis, suggesting a
speciﬁc disease-related risk [58]. Many are also inﬂuenced by
several factors, including patientsʼ characteristics [91], disease
characteristics [92–95], and lifestyle factors [60].Non-alcoholic fatty liver disease
Psoriasis
Several studies have found an increased incidence of NAFLD in
patients with psoriasis [96]. Gisondi et al. [97] demonstrated an
increased frequency of NAFLD in patients with psoriasis compared
with controls matched for age, sex, and body mass index (47% vs.
28%; p o 0.0001), with frequency linked to severity of psoriasis.
NAFLD is the most common liver disease in Indian patients with
psoriasis [98].Psoriatic arthritis
An Italian study found NAFLD to be independently associated
with psoriatic arthritis in patients with psoriasis [69]; regardless of
age, gender, BMI, and obesity, psoriatic arthritis was found to be a
predictor of NAFLD in patients who also had psoriasis.Rheumatoid arthritis
In the general population, NAFLD affects 10–24% of subjects,
increasing to 57.5–74% in the obese [99]. An assessment of autopsy
histologic liver abnormalities in patients with rheumatoid arthritis
indicated that 42 of 182 cases (23%) showed fatty changes [100].
Ultrasonography has shown 23% and 15% of patients with and
without rheumatoid arthritis to have NAFLD [101].
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Co-morbidities not only signiﬁcantly impact daily life in the
short term, but prolonged disease and associated co-morbidities
could also result in cumulative impairment in many aspects of a
patientʼs life, including their professional activities and ﬁnancial
status [7], and could contribute to reduced life expectancy [102].
Given the commonality of co-morbidities across all three
diseases, there is a degree of overlap in their management. For
example, it has been suggested that cardiovascular risk factors in
patients with psoriasis should be treated as aggressively as in
rheumatoid arthritis, with life-style interventions, and early statin
therapy [103].
A focus is needed on awareness, screening and treatment for
co-morbidities, including the potential impact on treatment
choices, by all involved (rheumatologists, dermatologists, general
practitioners, and patients alike), where an agreed care pathway
allows optimal treatment for patients. An integrated approach has
been proposed that uses algorithm-based management of co-
morbidities in the dermatology setting [104].Management: Current therapies and differential treatment
algorithms
Current therapies
Historically, most treatments for psoriasis, psoriatic arthritis,
and rheumatoid arthritis were developed empirically or found by
chance, and consisted of effective but non-targeted agents. The
early stages of these diseases are often still treated with these
established agents; methotrexate is an example of an effective
non-speciﬁc agent used in the treatment of psoriasis [5], early
stage psoriatic arthritis [42], and rheumatoid arthritis [21,105]
(Table 1).
However, our increased understanding of the immunopatho-
genesis of psoriasis, psoriatic arthritis, and rheumatoid arthritis
has led to the development of targeted treatments directed at bothTable 1
Relationship between mechanism of action and licensed indication: current systemic
European Union
Category Molecule Mechanism of action
Synthetic DMARDs/other Methotrexate Anti-metabolite [106]
Leﬂunomide Anti-metabolite [106]
Corticosteroids Direct and indirect immune mec
Hydroxychloroquinine Interference with antigen proces
Sulfasalazine Anti-inﬂammatory and antimicro
Minocycline Metalloproteinase inhibitor [110]
Cyclosporine T-cell-activation inhibitor [111]
Acitretin Activates retinoid acid receptor s
Fumaric acid Modulator of intracellular glutath
Apremilast PDE4 inhibitor [114]
Biologics Etanercept Recombinant human TNF-recepto
Inﬂiximab Humanized chimeric anti-TNF-α
Adalimumab Human monoclonal anti-TNF-α a
Golimumab TNF-α blocker [31]
Certolizumab TNF-α blocker [31]
Ustekinumab Anti-IL-12/IL-23p40 monoclonal
Anakinra IL-1-receptor antagonist [31]
Abatacept T-cell-activation inhibitor [31]
Rituximab CD20 inhibitor [31]
Tocilizumab IL-6-receptor inhibitor [31]
Secukinumab IL-17A antagonist [115]
CD, cluster of differentiation; DMARD, disease-modifying anti-rheumatic drug; IL, interlextracellular and intracellular signaling pathways implicated in
each disease.
Extracellular signaling pathways and targeted therapy
Extracellular signaling pathways transmit information between
cells by activating speciﬁc receptor proteins on the cell membrane.
Our increased understanding of the pathogenesis of psoriasis,
psoriatic arthritis, and rheumatoid arthritis has resulted in biologic
agents that speciﬁcally target key extracellular mechanisms
[5,21,42,105].
In general, large molecule biologics disrupt cytokine signaling
in the extracellular space by inhibiting receptor activation
[35,36,38,39,116]. This type of cytokine inhibition remains central
to the success of TNF blockers and biologics that block IL-6, IL-17,
IL-12, and IL-23 (Fig. 1B, Table 1).
Psoriasis. In response to increased patient serum concentrations of
the key cytokine, TNF-α, [36], three TNF inhibitors, etanercept,
inﬂiximab, and adalimumab, are currently used for the treatment
of psoriasis [38]. Etanercept competitively inhibits interactions of
TNF-α with cell-surface receptors and down-modulates Th17-
activated genes, cell products, and down-stream effector
molecules. Etanercept also decreases numbers of inﬁltrating T
cells, suggesting that its efﬁcacy may be due to a break in the cycle
of dendritic-cell and T-cell activation, and pro-inﬂammatory
mediator release [5,117,118]. In addition, etanercept may reduce
IL-22 and IL-17A serum levels [119]. Inﬂiximab reduces the cellular
inﬁltrate in psoriatic lesions, leading to normalization of
keratinocyte proliferation and differentiation [38]; it may also
impair differentiation of monocyte-derived dendritic cells and
activation of T cells [38,120]. Adalimumab reduces dendritic cell,
macrophage, and T-cell numbers, and normalizes keratinocyte
differentiation [121].
More recent therapies include ustekinumab which blocks
signaling of IL-12 and IL-23 [122,123]. A systematic review of
IL-12, IL-17, and IL-23 inhibitors for the treatment of moderate to
severe psoriasis suggested that these biologic agents were effective
[124]. The ﬁrst anti-IL-17 antibody, secukinumab [115], has beentherapies licensed for psoriasis, psoriatic arthritis, or rheumatoid arthritis in the
Indication
Psoriasis Psoriatic arthritis Rheumatoid arthritis
X X X
X X
hanisms [107] X X
sing [108] X
bial [109] X
X
X X
ubtypes [112] X
ione [113] X
X X
r fusion protein [31] X X X
monoclonal antibody [31] X X X
ntibody [31] X X X
X X
X X
antibody [31] X X
X
X
X
X
X X
eukin; TNF, tumor necrosis factor.
Table 2
Selected novel non-biologic agents approved in the USA and in development for the treatment of psoriasis, psoriatic arthritis, and rheumatoid arthritis
Molecule Target/mechanism of action Indication (FDA approved) or clinical phase
Psoriasis Psoriatic arthritis Rheumatoid arthritis
Tofacitinib JAK-1/3 inhibitor Phase 3 Phase 3 X
Apremilast PDE4 inhibitor X X –
Baricitinib JAK 1/JAK 2 inhibitor – – Phase 3
Ixekizumab Phase 3 Phase 3 Phase 2
CF101 A3 adenosine receptor agonist Phase 2/3 – Phase 2
AN2728 (topical) PDE4 inhibitor Phase 2 – –
ASP-015K JAK inhibitor Phase 2 – Phase 3
ACT-128800 S1P receptor agonist Phase 2 – –
VB-201 TLR-2/TLR-4 antagonist Phase 2 – –
GLPG0634 JAK-1 inhibitor – – Phase 2
CCX354-C CCR1 antagonist – – Phase 2
This table is not intended to be an exhaustive list of all novel non-biologic molecules in rheumatoid arthritis, psoriatic arthritis and psoriasis.
CCR, chemokine receptor; FDA, Food and Drug Administration; JAK, Janus kinase; PDE4, phosphodiesterase type 4; TLR, toll-like receptor improve efﬁcacy.
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moderate to severe psoriasis [125].
Psoriatic arthritis. Given the roles of T-cell activation, proliferation,
and differentiation, as well as cytokine release by T cells and
macrophages, in the pathogenesis of psoriatic arthritis [42], there
is growing support for agents that interfere with these events.
Due to the central importance of TNF-α in the pathophysiology
of psoriatic arthritis [10], the development of TNF-α inhibitors
represents one of the most signiﬁcant therapeutic advances in
psoriatic arthritis. TNF pathway upregulation may be similar in
skin and synovium [54], hence, agents have been successful in
controlling all aspects of the disease [10]. Etanercept, inﬂiximab,
adalimumab, golimumab, and certolizumab are currently used for
the treatment of psoriatic arthritis, often in combination with
synthetic DMARDs, although a recent analysis reported similar
responses to TNF inhibitors in patients with and without concom-
itant methotrexate [126]. A systematic literature review of drug
therapies for psoriatic arthritis concluded that there was goodFig. 2. Current treatment strategies for (A) psoriasis (reprinted from Menter et al. [6], c
[154], from BMJ Publishing Group Ltd.), and (C) rheumatoid arthritis (reproduced fro
Dermatology; ACR, American College of Rheumatology; DMARD, disease-modifying an
chloroquinine; LEF, leﬂunomide; MTX, methotrexate; NSAIDs, non-steroidal anti-inﬂamm
RA, rheumatoid arthritis; SSZ, sulfasalazine; TNF, tumor necrosis factor; UVB, ultraviolet
to activity; or damage; or past glucocorticoid use. **The treatment target is clinical remis
remission is the absence of signs and symptoms.evidence for the efﬁcacy of anti-TNF therapy and evidence to
support the use of non-steroidal anti-inﬂammatory drugs and
synthetic DMARDs (methotrexate, cyclosporine A, sulfasalazine,
and leﬂunomide) in this condition [127].
Other successful strategies include targeting phosphodiesterase
4, or the IL-17 or IL-12/23 pathways, although there is evidence
that these approaches may be less effective than anti-TNF therapy
[54,128,129]. Ustekinumab, an anti-IL-12/IL-23p40 treatment, was
approved for use in psoriatic arthritis by both the FDA and the
European Medicines Agency (EMA) in September 2013 [130,131].
Alternative targeted therapies include abatacept, a naïve T-cell co-
stimulatory blocker that has been shown in some studies to be
effective in psoriatic arthritis [132] although, to date, it has not
been approved for this use.
Rheumatoid arthritis. Signiﬁcant advances in the treatment of
rheumatoid arthritis have been made over the past 10 years with
the introduction of biologic therapies, including agents that
neutralize cytokines, such as TNF-α and IL-6. Many agents,opyright 2008, from Elsevier), (B) psoriatic arthritis (reproduced from Gossec et al.
m Singh et al. [105], from John Wiley & Sons, Inc.). AAD, American Academy of
ti-rheumatic drug; EULAR, European League Against Rheumatism; HCQ, hydroxy-
atory drugs; PsA, psoriatic arthritis; Pso, psoriasis; PUVA, psoralen þ ultraviolet A;
B. *Adverse prognostic factors: Z5 active joints; or high functional impairment due
sion or, if remission is unlikely to be achievable, at least low disease activity; clinical
Fig. 2. Continued
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function which, given the important role neutrophils play in the
pathogenesis of this disease [57], probably contribute to the
efﬁcacy of these agents [133,134].
Cell-targeted therapy capitalizes on the importance of both T
and B cells in the pathophysiology of rheumatoid arthritis [21,105].
Rituximab, a chimeric monoclonal antibody targeting the CD20
molecule expressed on B cells, and abatacept, a CTLA4-Ig fusionmolecule, are both effective in the treatment of rheumatoid
arthritis [116] (Table 1).
However, limitations associated with biologic therapy include
parenteral administration, cost, and they may have some undesir-
able side effects. As such, over the last several years, there have
been intensiﬁed efforts to develop small-molecule oral agents that
may represent less expensive, better tolerated, and more conven-
iently administered therapeutic options [135].
Fig. 2. Continued
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Intracellular signaling pathways transmit information to the
cytoplasm and the nucleus of the cell, and thereby regulate cellular
responses and gene transcription. Small molecule agents are able
to target these intracellular pathways to exert their effects (Fig. 1B)
[42,50,57,135-144], and include many non-biologic systemic
treatments with potential in psoriasis, psoriatic arthritis, and
rheumatoid arthritis (Table 2). For example, apremilast, an oral
phosphodiesterase-4 inhibitor [145], has received approval for the
treatment of psoriatic arthritis [146] and psoriasis [147].
The overlap in intracellular signaling cascades involved in the
pathophysiology of each disease provides a rationale for the use of
agents across psoriasis, psoriatic arthritis, and rheumatoid arthritis
(Fig. 1B). For example, IL-2, IL-6, IFNs, and the IL-12/23 axis utilizea variety of signaling cascades currently being investigated as
therapeutic targets for all three diseases. Small molecules can
block intracellular enzymes important in many signaling path-
ways. This is exempliﬁed by tofacitinib, an oral JAK inhibitor for
the treatment of rheumatoid arthritis [148–152] that is also being
investigated for psoriasis and psoriatic arthritis.
Differential treatment algorithms
The overall beneﬁt-risk ratio is central to the utilization of any
agent, and, even though some targeted immunotherapies are
highly efﬁcacious for psoriasis, psoriatic arthritis, and rheumatoid
arthritis [31], variations in disease immunopathogenesis and
patient demographics may mean that different mechanisms of
Fig. 3. Predicted innovations over the next 5 years for (A) psoriasis, (B) psoriatic arthritis, and (C) rheumatoid arthritis. IL, interleukin; JAK, Janus kinase; PDE,
phosphodiesterase; TNF, tumor necrosis factor.
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addition, the immunogenicity of an agent can result in the
production of anti-drug antibodies, thus preventing optimum
efﬁcacy, but this may differ between diseases, as both drug- and
disease-related factors can impact immunogenicity [153].
While there is much overlap in therapeutic approaches, the
differences between the diseases highlighted so far mean thatdistinct treatment algorithms exist for psoriasis [6], psoriatic
arthritis [154], and rheumatoid arthritis [105] (Fig. 2); these should
continuously evolve with new clinical evidence.
Combination therapy is an especially important strategy in the
clinical management of immunological diseases [155]. Methotrex-
ate in combination with etanercept has been shown to improve
efﬁcacy compared with monotherapy in rheumatoid arthritis
L.C. Coates et al. / Seminars in Arthritis and Rheumatism 46 (2016) 291–304300[156], and observational data support the use of methotrexate in
combination with TNF inhibitors in psoriatic arthritis in order to
improve their effective duration of therapy [157]. Data are required
comparing methotrexate with TNF inhibitors, or apremilast with
combination therapy, to clearly deﬁne treatment algorithms for
psoriatic arthritis. While there is evidence to suggest improved
efﬁcacy in patients with psoriasis treated with etanercept in
combination with methotrexate [158], most systemic treatments
in psoriasis are still currently recommended as monotherapy
[159]. Recent observational studies in patients with psoriasis have
also identiﬁed a loss of efﬁcacy of TNF inhibitors over time due to
anti-TNF antibodies [160–162], highlighting the need for a pro-
spective evaluation of the combination of TNF inhibitors with
methotrexate to reduce the development of anti-drug antibodies
and improve efﬁcacy.Current thoughts, agents in development, and future
perspectives
Established treatments for psoriasis, psoriatic arthritis, and
rheumatoid arthritis have not fully met the needs of patients,
and while there has been remarkable progress in the development
of new, highly effective targeted therapies, there are still many
challenges.
Our understanding of psoriasis, psoriatic arthritis, and rheuma-
toid arthritis reveals distinct differences between these diseases in
their pathogenesis [32,34,37,38], co-morbidities, and treatment
strategies [6,70,105,154,163–166]. The challenge in the manage-
ment of each disease lies in the selection of treatments targeting
immunopathological activity without affecting immunosurveil-
lance. Continued investigation into the immunopathogenesis of
psoriasis, psoriatic arthritis, and rheumatoid arthritis has resulted
in a pipeline of potential new drugs for these three diseases
(Fig. 3), and these agents could eventually complement theTable 3
Potentially predictive genetic, protein, and cellular biomarkers
Rheumatoid factor Serop
[18ACPA auto-antibodies
Apolipoprotein A-1 May
Low Type 1 IFN signature May
rhe
High B-cell count during treatment May
Calprotectin Syste
an
S100A9 protein S100
rhe
Myeloid related protein (MRP)8/14 Chan
[19
Tartrate-resistant acid phosphatase 5b (TRACP-5b) TRAC
rad
Micro (mi)RNA-125b Seru
art
IL-6 Seru
pre
Nitrotyrosine (NT) NT is
an
TNF-α genotypes TNFα
art
res
IL-12B/IL-23R polymorphisms IL-23
pso
HLA-Cw6 May
[19
IL36γ IL36γ
tre
Biomarker panel including S100A8, S100A10, Ig kappa chain C ﬁbrinogen-α and
γ, haptoglobin, annexin-A1 and A2, vitronectin, alpha-1 acid glycoprotein
Mult
[18
ACPA, anti-citrullinated protein antibodies; HLA, human leukocyte antigen; IFN, interfertraditional systemic treatments and biological agents that are
currently available [116].
Given increasing knowledge of the pathogenesis of psoriasis,
psoriatic arthritis, and rheumatoid arthritis, and differing drug
efﬁcacy and safety proﬁles between diseases [95,167,168], it is
hoped that advances in genetic analyses [28,169-180] together
with the progress made in targeted therapy, may allow treatment
to be tailored on the basis of an individualʼs genetic and immuno-
logical proﬁle.
For this goal to be realized, one key requirement is the clear
deﬁnition of disease subsets so that treatment regimens can be
targeted at patients who are most likely to respond. This in turn
requires the identiﬁcation of genetic, protein, and cellular bio-
markers that accurately predict patientsʼ therapeutic response.
Pitzalis and colleagues have recently proposed that speciﬁc path-
ways within synovial tissues that may be associated with ther-
apeutic responses in patients with rheumatoid arthritis could be
used as a potential clinical tool for patient treatment stratiﬁcation
[181]. In fact, a recent study has demonstrated that a panel of
synovial-derived proteins can identify biologic responders at base-
line [182].
Despite the availability of a variety of potentially predictive
biomarkers (Table 3), there is still signiﬁcant unmet need in these
inﬂammatory disorders. Targeted agents have been useful in
dissecting disease pathogenesis, and intracellular agents remain
viable treatment options. Finally, we suggest that future research
agendas should include the effects of different therapies on co-
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